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Low molecular weight (LMW) heparin inhibits
injury-induced femoral artery remodeling in
mouse via upregulating CD44 expression
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Shuennwen Kuo, MD,a,c and Charles A. Hales, MD,a Boston, Mass; Zhengzhou, China; and Taipei, Taiwan
Objective: The mechanism of postangioplasty restenosis remains poorly understood. Low molecular weight (LMW)
heparin has been shown to inhibit the proliferation of vascular smooth muscle cells (VSMCs), which is the principal
characteristic of restenosis. Studies have shown that LMW heparin could bind to CD44. We hypothesized that LMW
heparin might modulate CD44 expression thereby decreasing vascular remodeling.
Methods: Vascular remodeling was induced in CD44/ and CD44/mice and treated with LMW heparin. The arteries
were harvested for histologic assessment and determination of CD44 expression. Bone marrow transplantation was
introduced to further explore the role and functional sites of CD44. Effects of LMW heparin on growth capacity, CD44
expression were further studied using the cultured mouse VSMCs.
Results: Transluminal injury induced remarkable remodeling in mouse femoral artery (sham wall thickness percentage
[WT%]: 3.4  1.2% vs injury WT%: 31.8  4.7%; P < .001). LMW heparin reduced the remodeling significantly (WT%:
17.8 3.5%, P< .005). CD44/mice demonstrated considerably thicker arterial wall remodeling (WT%: 46.2 7.6%,
P  .0035), and CD44-chimeric mice exhibited equal contributions of the local and circulating CD44 signal to the
neointima formation. LMW heparin markedly upregulated CD44 expression in the injured femoral arteries. In vitro,
LMW heparin decreased mouse VSMC growth capacity and upregulated its CD44 expression simultaneously in a
dose-dependent and time-dependent manner, which could be partially blocked by CD44 inhibitor.
Conclusions: LMW heparin inhibits injury-induced femoral artery remodeling, at least partially, by upregulating CD44
expression. (J Vasc Surg 2011;53:1359-67.)
Clinical Relevance: Angioplasty is widely used in clinical practice to treat various stenostic vascular disorders, but the
postangioplasty reocclusion has been a big limit and the mechanism underlying the vascular remodeling remains poorly
understood. LMW heparin has been a promising medicine to inhibit VSMC proliferation. However, the mechanism of
LMW heparin inhibition against smooth muscle cell (SMC) proliferation and its clinical usefulness is still not clear. Our
present data, which were based on in vivo and in vitro studies, suggested that LMW heparin induced higher CD44
expression in VSMCs, and through the CD44 pathway, LMW heparin significantly reduced SMC proliferation and
injury-induced femoral artery remodeling. Our study clarified the roles of LMW heparin in vascular occlusive diseases.
This study helps to elucidate the underlying cellular and molecular mechanism by which LMW heparin inhibits
injury-induced remodeling and could promote creating new therapeutics to control the exaggerated neointimal hyper-
plasia.
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PAngioplasty is a commonly used treatment for various
occlusive lesions. However, there are many risks associated
with this treatment. One such risk is restenosis. Restenosis
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doi:10.1016/j.jvs.2010.11.048fter angioplasty has been a major limitation in the long-
erm prognosis of this treatment. Althoughmuch effort has
een devoted to understanding this complication, the
echanism underlying the remodeling of the arterial vas-
ulature remains poorly understood.1,2 One principal char-
cteristic of restenosis is the prominent accumulation of
ascular smooth muscle cells (VSMCs). VSMCs have been
ne of the key targets in prevention and treatment of
cclusive vessel diseases.3
Low molecular weight (LMW) heparin is a glycosami-
oglycan that is clinically used as an antithrombotic agent.
MW heparin has been shown to inhibit VSMC prolifera-
ion.4 Our previous studies have indicated that LMW hep-
rin inhibits pulmonary vascular remodeling in bovine and
odent models,5,6 but the mechanism of this inhibition is
ot well understood.
CD44 is a specific cell-surface receptor for hyaluronan.
revious studies have revealed that it is one of the target
enes of high-mobility-group proteins, which plays a major
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May 20111360 Zhao et alrole in the development of atherosclerotic lesions, charac-
terized by VSMC proliferation.7,8 Kothapalli found that
CD44 showed antimitogenic effects and was associated
with altered VSMC proliferation.9 Harris documented that
free LMW heparin could bind to hyaluronan and CD44 to
form a compound.10 However, there are few studies defin-
ing the role of CD44 in arterial proliferative lesion, and it is
not clear whether LMW heparin modulates CD44 expres-
sion in vascular remodeling.
We developed an injury-induced vascular remodeling
model by temporally placing a spring guidewire into a
mouse femoral artery. Using this model, we designed the
present study to understand the roles of LMW heparin and
CD44 in arterial remodeling, as well as the effects of LMW
heparin on CD44 expression.
METHODS AND MATERIALS
Animals. Six- to 8-week-old inbred male CD44
knockout mice (CD44/, Genotype: CD44 tm1Hbg /J)
and wild-type control mice (CD44/, C57BL/6J),
weighing 21 to 25 g, were obtained from the Jackson
Laboratory, Bar Harbor, Me. All the procedures were
performed in accordance with protocols approved by the
Subcommittee on Research Animal Care at Massachusetts
General Hospital, Harvard University and in compliance
with the “Guide for the Care and Use of Laboratory
Animals” (Publication No. NIH 78-23, 1996). The
CD44/ mice used in the present work were viable,
fertile, and normal in size. They did not display any gross
physical or behavioral abnormalities. No CD44 gene prod-
ucts (mRNA or protein) were detected in these mice.
Mouse transluminal injury-induced femoral ar-
tery remodeling. Mice were randomly placed into var-
ious experimental groups (CD44/ sham; CD44/
injury; CD44/ injury/heparin; CD44/ injury/saline;
CD44/ injury/warfarin; CD44/ sham; CD44/
injury; CD44/ injury/ heparin). Five mice were used
in each group. To achieve a surgical level of anesthesia,
the mice were anesthetized by intraperitoneal injection of
50 mg/kg ketamine hydrochloride diluted in 0.9% sodium
chloride solution. The surgical procedure used was a sim-
plified version of one previously described byMasataka Sata
and Ernane Reis.11,12 Briefly, a groin-to-knee incision was
made in the left hind leg and the femoral artery was dis-
sected. Through a muscular branch between the rectus
femoris and vastus medialis muscles, a spring guidewire
(0.38 mm in diameter, No. C-SF-15-15; Cook, Blooming-
ton, Ind) was gently advanced into the femoral artery at
least 6 mm in-depth and kept in place for 20 seconds. The
femoral artery blood flow was restored after the surgery.
The mice were euthanized at fixed endpoints, and the
femoral arteries underwent perfusion fixation by flushing
0.9% sodium chloride solution followed by 10% parafor-
maldehyde buffer (pH 7.4) through the left ventricle. The
vessels were then carefully harvested and postfixed in 10%
paraformaldehyde buffer (pH 7.4).
A time course of remodeling was investigated by har-
vesting the femoral arteries from CD44/mice at weekly eime points, week 1 through week 7 postsurgery. There
ere five mice in each time point group.
We determined the dose of LMW heparin by titration
o achieve the most effective action while avoiding its
oxicity. As previously described,6 the mice under heparin
reatment (five mice included in each group) were given 20
g/kg of LMW heparin (heparin sodium salt; MP Bio-
edicals, LLC, Solon, Ohio) subcutaneously once a day for
weeks. The first loading dose of 40 mg/kg was adminis-
ered subcutaneously 1 hour prior to the surgery. In the
ham group (five mice were included), the surgery was
erformed without transluminal injury. The purity of
MW heparin was tested by capillary electrophoresis and
soelectric focusing/two-dimensional electrophoresis by
P Biomedicals, LLC to exclude any contamination, and
he purity was found to be 99.8%.
To determine whether the antiproliferative action of
MW heparin was due to its anticoagulant property, we
ompared the effect of warfarin (Coumadin; DuPont Phar-
aceuticals, Wilmington, Del), a thrombin inhibitor, given
t an anticoagulant dose of 0.25 mg/kg/d subcutaneously
SC) with a loading dose of 0.5 mg/kg/d for 3 days prior
o the surgery to LMW heparin. We established a dose of
arfarin that would exhibit equal ability as LMWheparin to
nhibit thrombin generation determined by prothrombin
ime (PT) test. Mice treated with warfarin (0.25 mg/kg/d
C) or LMW heparin (20 mg/kg/d SC) presented an
dentical increase in PT from the normal range of 10  3 to
5 8.3 seconds without any accompanying toxicity.
Elastin Van Gieson staining and histopathologic
nalysis. The perfusion-fixed mouse common femoral ar-
eries were cut into two 2- to 3-mm segments for paraffin
mbedding. Multiple cross-sections (5 m) of both seg-
ents underwent elastin Van Gieson staining of the inter-
al elastic lamina for accurate measurement of the neoin-
ima. Each group included at least five femoral arteries, and
ny arteries which appeared to contain thrombi were ex-
luded from the evaluation. Digitized images were ana-
yzed with image analysis software ImageJ v. 1.33 u (NIH)
y two blinded investigators independently. Mean remod-
ling values were obtained via averaging the values from
ach animal in the same group. The technique used to
easure wall thickness percentage (WT%) is described in
he supplement section (Appendix, online only) of this
rticle. For the histologic assessment, five mice were used in
ach group under various experimental conditions.
Western blot analysis. Western blot analysis was per-
ormed as previously described.5 Protein was extracted
rom the femoral arteries of each group (fivemice were used
n each group) or cultured mouse VSMCs. CD44 antibody
rabbit polyclonal antibody; Abcam Inc, Cambridge, Mass)
nd GAPDH (mouse monoclonal antibody, Research Di-
gnostics Inc, Flanders, NJ) were used for Western blot
etection.
Bone marrow transplantation. To further elucidate
hether CD44 was involved and to examine the contribu-
ive sites of CD44 signaling in the neointima formation, we
stablished CD44 chimeric mice by bone marrow trans-
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Volume 53, Number 5 Zhao et al 1361plantation. Bone marrow cells were harvested from femurs
and tibias of female CD44/ or CD44/mice. Femoral
artery injuries were performed 6 weeks after the bone
marrow transplantation. Two types of chimeric mice were
created: CD44/ mice with CD44/ bone marrow
(KO-WT) and CD44/ mice with CD44/ bone mar-
row (WT-KO). CD44/ with CD44/ bone marrow
(KO-KO) and CD44/ with CD44/ bone marrow
(WT-WT) were prepared as control groups at the same
time. In every group, one mouse was used as bone marrow
donor, and transplantations were performed on five receipt
mice. We harvested the femoral arteries from the receipts 4
weeks postsurgery for the histologic assessment.
Mouse vascular smooth muscle cell culture. Having
not found any difference betweenmouse thoracic/abdominal
aorta and femoral artery VSMCs, we chose to isolate tho-
racic and abdominal aorta VSMCs from the mice of each
group (five mice per group). Isolation of the VSMCs was
done by scraping the endothelium and removing the ad-
ventitia of the arteries microscopically. The media was
washed twice with reduced-Ca2 HBSS. The media was
cut into small pieces and then digested in reduced-Ca2
HBSS containing collagenase (1750 U/mL), papain (9.5
U/mL), bovine serum albumin (2 mg/mL), and dithio-
threitol (1 Mm/mL) at 37°C for 10 minutes. Then, the
cells were seeded and cultured in smooth muscle basal
medium with 10% fetal bovine serum (FBS; Vitromex,
Vilshofen, Germany), streptomycin, 100 g/mL (Invitro-
gen Life Technologies, Carlsbad, Calif) and penicillin, 100
g/mL (Invitrogen Life Technologies).
Growth inhibition analysis on cultured VSMCs. As
previously described,5 growth inhibition analysis was intro-
duced to assess the most effective antiproliferative dose of
LMW heparin for in vitro assay. VSMCs between passages
four and six were used to perform this study. The
CD44/VSMCs were seeded at 1.25 104 cells per well
in 6-well tissue culture plates and grown for 2 days in
regular medium (10% FBS). The cells were then divided
into three groups. Group one, the negative control, in-
cluded cells cultured in 10% FBS. Group two included cells
cultured in 0.1% FBS and used as a positive control. Group
three included cells cultured in 10% FBS at various concen-
trations of LMW heparin (10, 25, 50, 100, 150, and 200
g/mL) to determine the most effective antiproliferative
dose of LMW heparin. All groups were cultured for 5 days,
with the medium being changed daily. The cells were
harvested and stained with Trypan blue and counted using
a hemocytometer. Each group included five wells of cells.
The experiment was repeated three times. The method
used to calculate the percentage of growth inhibition (%
inhibition) is presented in the supplement section (Appen-
dix, online only). Five mice were used as VSMC donors.
Growth curves analysis on cultured VSMCs.
Growth curve analysis was introduced to study the antipro-
liferative action of LMW heparin on the cultured mouse
VSMCs (CD44/ and CD44/). VSMCs between pas-
sages four and six were used to perform this study. We
performed growth curve analysis on CD44/ VSMCs gultured in standard medium (10% FBS) and standard
edium with 100 g/mL LMW heparin, standard me-
ium with 6 g/mL anti-CD44 mAb (BD Biosciences,
ranklin Lakes, NJ), and standard medium with 100
g/mL LMW heparin as well as 6 g/mL anti-CD44
Ab. Similarly, growth curve analysis on CD44/
SMCs was performed in standard medium (10% FBS) and
tandard medium with 100 g/mL LMW heparin. Cells
rom five wells of each group were harvested and stained
ith Trypan blue and counted daily using a hemocytome-
er. The experiment was repeated three times. Five mice
ere used as VSMC donors.
Flow cytometry detection of CD44 expression on
ultured VSMCs. VSMCs between passages four and six
ere used to perform this study. Mouse smooth muscle
ells (SMCs) were seeded at 1.25  104 cells per well in
-well tissue culture plates and allowed to grow for 2 days.
he cells were then growth-arrested in 0.1% FBS for 48
ours and cultured for 5 days in standard medium (10%
BS) containing 100 g/mL LMW heparin. The medium
as replaced daily. CD44 expression on VSMCs was de-
ected by one-color flow cytometry analysis. Five mice were
sed as VSMC donors.
Time course of CD44 expression on cultured
SMCs. A time course study was performed to evaluate
he effect of LMW heparin on CD44 expression in vitro.
SMCs between the four to six passages were seeded at
.25  104 cells per well in 6-well tissue culture plates,
llowed to grow for 2 days, then growth-arrested in 0.1%
BS for 48 hours and then cultured in standard medium
ith 100 g/mL LMW heparin for 5 days. The medium
as replaced daily and the expressions of CD44mRNA and
rotein were detected daily. Five mice were used as VSMC
onors.
Statistical analysis. Data were presented as mean 
EM and analyzed by one- and two-way analysis of vari-
nce. Individual group means were compared with Stu-
ent’s unpaired t test. The statistical threshold was set at
 .05.
ESULTS
Transluminal injury induced neointima lesion and
MW heparin inhibited the remodeling in CD44 /
ice. Transluminal injury induced significant remodeling
n mouse femoral arteries, which was characteristic of neo-
ntima formation. After harvesting the vessels, we cut them
nto two 2- to 3-mm segments and embedded, respectively.
he resultant data of the two segments were averaged to
btain the mean remodeling values. The injured parts were
ncluded in the samples and the two segments of one
ample presented very similar thickness in remodeling. We
ccasionally encountered some thrombi in some mice in-
ucing mild remodeling in the involved arteries. The total
ncidence was 5%. We excluded these samples from our
valuation. The time course study revealed that the neoin-
ima was first noticeable 1 week after injury and reached a
eak thickness in the fourth week (Fig 1, A). We investi-
ated the remodeling for up to 12 weeks postinjury and
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May 20111362 Zhao et alfound that after 4 weeks, the vascular wall remodeling was
quite stable at a milder remodeling level.
Hence, we chose the end of the fourth week as the end
time point to assess histologic changes. LMW heparin-
treated CD44 / mice, which received transluminal
injury surgery, showed a remarkable reduction in remodel-
ing (Fig 1, B). By contrast, injured arteries treated with
warfarin or saline did not show any changes in remodeling
thickness, indicating that the beneficial effect of LMW
heparin on injury-induced vascular remodeling might not
be related to its anticoagulant property.
Involvement of CD44 in remodeling. Compared
with injured femoral arteries in CD44 / mice, the
CD44 / mice showed significantly thicker femoral
vascular remodeling (P  .0035), which indicates the in-
volvement of the CD44 gene in neointima formation. This
suggests that CD44 might play an inhibitory role in the
pathogenesis and development of injury-induced femoral
remodeling in mice (Fig 2, A).
Bone marrow transplantation was introduced to fur-
ther determine the role of CD44 as well as the contributive
sites of CD44 signaling to the development of neointima.
We documented that CD44/mice given CD44/
marrow (KO-KO, positive control) demonstrated mark-
edly thicker arterial remodeling (WT%: 32.4  5.5%) than
Fig 1. Time course of injury-induced femoral arterial re
heparin on remodeling lesion in CD44/mice. Transl
The neointima emerged at the end of the first week and p
artery; b. one week after injury, HE staining, arrow indica
e, f, g, and h represent remodeling of 2 weeks through 7 w
arrows indicate internal elastic laminas. Bar 5 m). In co
CD44/mice, LMW heparin reduced the wall remod
of vascular remodeling (B, Elastin vanGieson staining, ar
n  5.that in CD44/ mice given CD44/ bone marrow nWT-WT, negative control; WT%: 17.7  1.9%; P  .0013),
ndicating the involvement of CD44 signaling in the re-
odeling process. CD44/ mice given CD44/ bone
arrow (WT-KO) presented significantly thicker vascular
emodeling (WT%: 23.2 4.6%) when compared with that
nWT-WTmice (P .009), suggesting the contribution of
ocal CD44 signaling to neointima formation. Similarly,
tatistically thicker vascular remodeling in CD44/ mice
iven CD44/ marrow (KO-WT, WT%: 21.6  3.7%)
as recorded when compared with that in WT-WTmice (P
.024), suggesting the contribution of circulating CD44
o the remodeling formation. Both groups of chimeric mice
WT-KO and KO-WT) had statistically thinner remodel-
ng compared with KO-KO mice (P  .005), which
urther demonstrated the contributions of both local and
irculating CD44. The WT-KO and KO-WT chimeric
roups did not differ in neointima thickness (P  .266)
ndicating the equal contribution of local and circulating
D44 to the neointima formation (Fig 2, B).
LMW heparin upregulated CD44 expression in re-
odeled femoral arteries. Compared with the unin-
ured arteries, the remodeled femoral arteries did not
how any appreciable change in CD44 expression.
hereas, when they were treated with LMW heparin, the
njured arteries demonstrated a remarkable reduction in
ling and the inhibition of low molecular weight (LMW)
al injury inducedmarked remodeling in CD44/mice.
d in the fourth week after the injury (A, a. sham femoral
thin neointima lying on the internal elastic lamina; c, d,
fter the injury, respectively. Elastin van Gieson staining,
t with the untreated, saline-treated and warfarin-treated
significantly, indicating an inhibitory role in the process
ndicate internal elastic laminas. Bar 5m). Each group,mode
umin
eake
tes a
eeks a
ntras
eling
rows ieointima thickness and a significant increase in CD44
rnal elastic laminas. Bar 5 m). Each group, n  5.
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Volume 53, Number 5 Zhao et al 1363expression (Fig 3). This suggested CD44 might be a
pathway by which LMW heparin decreased the remod-
eling. By contrast, warfarin or saline-treated injured
femoral arteries did not show any changes in remodeling
thickness or CD44 expression.
LMW heparin did not inhibit the vascular remod-
eling in CD44/ mice. When LMW heparin was ad-
ministrated to the injured CD44/ mouse, we found no
significant reduction in neointima formation compared
with the untreated CD44/ femoral arterial neointima
(42.7  4.1% vs 46.2  7.6%, P  .05). By contrast, the
LMWheparin-treated CD44/mice showed a significant
reduction in remodeled wall thickness (18.6  4.6%, P 
.005). These histologic results suggest that LMW heparin
exerts its antiproliferative effect on the vascular remodeling
lesion, at least partially, via CD44 signal pathway (Fig 4).
LMW heparin did not inhibit the growth of cul-
tured CD44 / VSMCs. LMW heparin was adminis-
tered at different doses to cultured CD44/ VSMCs.
Based on the inhibition analysis, we found that LMWheparin
inhibited mouse VSMCs growth in a dose-dependent manner.
At increasing LMW heparin concentrations, the growth ca-
pacities of the cultured VSMCs decreased, respectively.
Fig 2. Involvement of CD44 in the remodeling and th
Postinjury remodeling in CD44 / mouse femoral ar
indicating the involvement and an inhibitory role of CD
Elastin van Gieson staining; a, b, and c represent sham, C
indicate internal elastic laminas. Bar 5 m). CD44/
increased remodeling compared with CD44/ mice gi
.0013). Statistically thicker vascular remodeling in CD44
when compared to WT-WT. Both chimeric groups (WT
to CD44/mice given CD44/ marrow (KO-KO, po
groups did not differ in neointima thickness (P .266), in
signal to the neointima formation (B,Elastin vanGieson s
KO-WT femoral artery, respectively. Arrows indicate intee contributive sites of CD44 signal to neointima formation.
teries was significantly thicker than that in CD44 / mice,
44 gene in the development of the remodeling lesion. (A:
D44/ and CD44/ femoral arteries, respectively. Arrows
mice given CD44/ marrow (WT-KO) had significantly
ven CD44/ bone marrow (WT-WT, negative control. P 
/ mice given CD44/ marrow (KO-WT) was recorded
-KO and KO-WT) have much thinner remodeling compared
sitive control. P  .005). The WT-KO and KO-WT chimeric
dicating the equal contribution of local and circulating CD44
taining, a, b, c and d representWT-WT,KO-KO,WT-KO, andMuch higher concentrations of LMW heparin, 150 and Gig 3. Lowmolecular weight (LMW) heparin upregulated CD44
xpression in the injured CD44 / femoral arteries. In
D44/ mice, the injured arteries did not show a significant
hange of CD44 expression compared with the uninjured
D44/ mice. When treated with LMW heparin, the injured
emoral arteries expressed much higher CD44 protein (Western
lot detection of CD44 protein) in the fourth week after the injury,
hereas warfarin or saline did not affect the expression of CD44.
ADPH, Glyceraldehyde-3-phosphate dehydrogenase.
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May 20111364 Zhao et al200 g/mL, were noticed to induce death in a fraction
of VSMCs (the inhibition percentages were 112.5% and
134.2%, respectively), and, hence, 100 g/mL was de-
termined as the optimal concentration for in vitro assay
(Fig 5, A).
We compared the growth capacity of LMW heparin-
treated CD44/ VSMCs to that of the untreated
CD44/ VSMCs. No significant reduction in growth
capacity was observed in the LMW heparin-treated
CD44/ VSMCs. However, the LMW heparin-treated
CD44/ VSMCs demonstrated a significant decrease in
growth capacity when compared with the untreated
CD44/ SMCs (P  .001). This inhibitory ability of
LMW heparin on VSMCs growth could be partially
blocked by anti-CD44 mAb (Fig 5, B).
CD44 intensity and time course of LMW heparin
effect on CD44 expression on cultured mouse VSMCs.
Immuno-identification of CD44 expression was detected
by one-color flow cytometry analysis. Compared with the
non-LMW heparin-treated VSMCs, LMW heparin-treated
VSMCs exhibited significantly higher CD44 intensity on
the cellular surface, suggesting that LMW heparin upregu-
lated theCD44 expression on the culturedVSMCs (Fig 6,A).
CD44/VSMCswere cultured with LMWheparin at
100 g/mL and CD44 expression was examined daily. We
found LMW heparin upregulated CD44 expression in the
cultured VSMCs. CD44 expression increased gradually and
reached the highest level on the fourth day. The expression
trend was evaluated after day 5 and revealed that it is quite
stable after 5 days, at a relatively lower level. These data are
not included. Day 4 is the peak time of CD44 expression
induced by LMW heparin, which suggests that LMW hep-
arin upregulated CD44 expression in the cultured VSMCs
Fig 4. Effects of low molecular weight (LMW) heparin on the
remodeling of CD44/ femoral arteries In injured CD44/
mice, LMWheparin did not inhibit the remodeling compared with
the non-LMW heparin-treated CD44/ femoral arteries
(CD44/ vs CD44//LMW heparin; P  .05). LMW heparin-
treated CD44/ mice exhibited significant reduction in remod-
eling (CD44//LMW heparin vs CD44//LMW heparin P 
.001; CD44/ vs CD44//LMW heparin P  .005), indicating
the possible CD44 pathway through which LMW heparin inhib-
ited the remodeling. (Elastin van Gieson staining. Arrows indicate
internal elastic laminas. Each group, n  5).in a time-dependent manner (Fig 6, B). (ISCUSSION
The underlying mechanism responsible for restenosis
fter successful angioplasty remains incompletely under-
tood. Previous studies have suggested that LMW heparin
ould inhibit VSMC proliferation, which is the major
athologic change in occlusive disease.13,14 CD44 is an
mportant cell-surface specific receptor for hyaluronan.15
here are very few studies defining the role of CD44 in the
njury-induced remodeling lesions and some studies have
hown controversial results.16,17 The present study was
esigned to investigate whether LMW heparin can inhibit
he remodeling of injured femoral arteries in mice and
urthermore to elucidate the underlying mechanism.
Our previous studies have shown that LMW heparin
nhibited bovine VSMC growth and pulmonary vascular
emodeling induced by hypoxia in rodents.5,6 Vascular
tenosis and postangioplasty restenosis are typically VSMC
roliferative lesions. It is reasonable to hypothesize that
MW heparin could ameliorate the pathologic vascular
emodeling in femoral arteries. Clinical studies did not
how any beneficial effects of LMW heparin on human
ascular restenosis.2 We developed the present mouse
odel of transluminal injury such that it might resemble
linical angioplasty and document that LMW heparin in-
uces a significant reduction of neointima formation. By
ontrast, warfarin had no effects on the remodeling. These
esults strongly indicate that LMW heparin’s beneficial role
n inhibiting the proliferative lesion was not related to its
nticoagulant property. Some researchers postulated that
eparin inhibited smooth muscle cell growth by suppress-
ng the expression of matrix-degrading enzymes and inter-
titial collagenase.18 Other studies have shown that heparin
revented growth factors from binding to their receptors,
ecreasing oncogene expression at the injured site of the
rtery wall.19-21 However, the mechanism by which hepa-
in works as an inhibitor against arterial remodeling and
hy human clinical studies have shown negative results still
emain unknown.
The role that CD44 plays during the process of post-
ngioplasty remodeling is unclear. Some researchers have
eported increased CD44 expression in the neointima,
mplying that CD44 might be a promoting factor that
nhances the remodeling process, while others have re-
orted that CD44 might play a protective role inhibiting
eointima formation.22,23 We found that the targeted de-
ciency of the CD44 gene significantly enhanced neointi-
al hyperplasia, suggesting that the CD44 gene has impli-
ations in the pathologic remodeling process and might
lay a protective role.
The remodeling response to injury involves the circu-
ating cells that arise from the bone marrow as well as cells
rom the local arterial wall.24 CD44 chimeric data demon-
trated that both types of chimeric mice with deficient
D44 signal (WT-KO and KO-WT) presented thicker
eointima. Mice deficient in all cells (KO-KO) presented
ith much thicker remodeling than chimeric mice
WT-KO and KO-WT), and both types of chimeric mice
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cated that CD44 signal was involved in the process of
neointima formation and both the local CD44 signal in the
vessel wall and circulating CD44 signal contributed equally
to neointima formation in this model.
CD44 is a transmembrane glycoprotein and works as a
principal cell receptor for hyaluronic acid, interacting with
many extracellular matrix molecules and intracellular sig-
naling molecules.25 Kothapalli revealed that CD44 pos-
sessed an antiproliferative function mediated by differential
activation of ERK and Rac genes.26 Various mechanisms
have been proposed, but the biological behavior of CD44 is
Fig 5. Growth inhibition and growth capacity analysis o
Growth inhibition analysis showed low molecular weig
dependent manner. Along with the increasing concentrat
cultured VSMCs were documented. Conversely, concent
to induce death in a fraction of VSMCs (the inhibition pe
100 g/mL demonstrated the highest inhibition on VSM
analysis indicated that LMW heparin significantly inhibit
this effect could be partially blocked by the anti-CD44 m
significant effect on the growth capacity of cultured CD
Fig 6. CD44 intensity and time course study on CD44 e
molecular weight (LMW) heparin. Immuno-identifica
cytometry analysis and indicated that LMW heparin indu
vascular smooth muscle cells (VSMCs). (A: flow cytometr
and c represent untreated, saline-treated and LMW hepa
heparin-treated VSMCs, P .005; untreated VSMCs vs sal
of LMW heparin at a concentration of 100 g/mL on th
CD44 expression in a time-dependent manner, which
Western blot detection of CD44 expression).multivariant, controversial, and still unclear. sInterestingly, we documented that LMW heparin
ignificantly upregulated CD44 expression in neointima.
urthermore, LMW heparin did not reduce the remod-
ling in injured CD44/ mice. Additionally, immuno-
dentification of CD44 expression demonstrated that
MW heparin induced higher CD44 intensity on the
ultured mouse VSMCs. These results suggested that
MW heparin might inhibit the remodeling lesion via
he CD44 pathway. Meanwhile, LMW heparin reduced
SMCs proliferative capacity, and this action could be
artially blocked by anti-CD44 mAb. The in vitro find-
ngs were consistent with what we found in the in vivo
cultured mouse vascular smooth muscle cells (VSMCs).
MW) heparin inhibited the cellular growth in a dose-
the higher inhibition capacities of LMW heparin on the
ns of LMW heparin at 150 and 200 g/mL were noted
ages were both greater than 100%). The concentration of
rowth without causing cells to die (A). Growth capacity
e proliferation of the cultured CD44 / VSMCs and
t a dose of 6 g/mL (P  .001). LMW heparin had no
 VSMCs (P  .05) (B).
ssion on the cultured mouse VSMCs incubated with low
f CD44 intensity was performed by one-color flow
arkedly higher CD44 expression on the cultured mouse
lysis of the CD44 expression on the cultured VSMCs, a, b,
reated VSMCs, respectively. Untreated VSMCs vs LMW
eated VSMCs, P .05). Time course study on the effects
ression of CD44 revealed that LMW heparin increased
ed the highest level on the fourth incubating day (B:n the
ht (L
ions,
ratio
rcent
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reachtudies. Taken together, we postulated that LMW hep-
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in the mouse, at least partially, via upregulating CD44
expression. Kaya reported that heparin might bind to
EGF and its receptor and complex with CD44, influenc-
ing CD44 expression.27 However, how LMW heparin
upregulates the expression of CD44 is still poorly under-
stood.
The outcomes of these studies have potential clinical
implications in treating stenotic vascular disease. VSMC
proliferation is the major cause of vascular restenosis. A
critical player in regulating VSMC proliferation is CD44
and may represent a target for clinical therapeutic interven-
tion. The finding that heparin upregulates CD44 expres-
sion on SMCs suggests that it could be a theoretically
practical tool in the upregulation of CD44 expression on
VSMCs. In addition, recent technological advances permit
the structural modification of heparin to achieve variants of
heparin with stronger antiproliferative property and less
anticoagulant activity. Although the present research has
clinical significance, its use is still a long way from being
applicable to actual clinical practice. More work should be
performed to elucidate the underlying mechanisms by
which heparin prohibits VSMC proliferation, as well as the
creation, testing, and selecting of modified heparin vari-
ants, before clinical practice may begin.
Collectively, our data suggested that LMW heparin
induced higher CD44 expression in VSMCs and that
CD44 might play a previously unrecognized role in pre-
venting neointima formation in mice. However, the cur-
rent study has certain limitations, such as how LMW hep-
arin upregulates CD44 expression and whether LMW
heparin affects CD44 expression directly or indirectly. The
current study also did not address the role of other genes or
factors that might be implicated in the interaction of LMW
heparin, CD44 and remodeling, or if these results can be
extrapolated to human studies and what the real clinical
benefit might be. More studies are still needed to clarify the
underlying mechanism of vascular occlusive diseases (Sup-
plementary Figures 1-5, online only).
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How to calculate the inhibition rate of heparin on
cultured VSMCs
Average count of 10% FBS  average of raw counts of
5 wells of VSMCs cultured in 10% FBS
Average count of 0.1% FBS average of raw counts of
5 wells of VSMCs cultured in 0.1% FBS
Net average of 10% FBS average count of 10% FBS
Average count of 0.1% FBS
Note:
Inhibition of 10% FBS is theoretically regarded as 0%
Inhibition of 0.1% FBS is theoretically regarded as
100%
Inhibition100%means a fraction of cultured cells are
induced to die
% Inhibition
1
Raw count of samples Average count of 0.1% FBS
Net average of 10% FBS
 100%
Methods and materials
Elastin van Gieson staining. Cross-section slides
were deparaffinized and hydrated in distilled water and
then underwent Elastin van Gieson staining. These sections
were first stained in Verhoff’s solution for 30 minutes and
then rinsed in tap water for 5 minutes. Sections were
subsequently incubated in 2% aqueous ferric chloride solu-
tion for 3 minutes and rinsed in tap water for 2 minutes.
Next, the sections were treated in 5% sodium thiosulfate for
2 minutes and rinsed in tap water for 5 minutes. Finally, the
sections were counterstained in van Gieson’s solution for 5
minutes and then dehydrated and covered for morphomet-
ric analysis.
Immunohistochemistry assessment. Following theman-
ufacturer’s protocol, we used labeled-strepavidin-biotin (LSAB)
immunohistochemical kit (Histostain-plus kit; Zymed Lab- Sratory, Inc, Carlsbad, Calif) to detect CD44 protein (rab-
it polyclonal antibody; Abcam Inc, Cambridge, Mass) in
he femoral arterial neointima. Hematoxylin was used as a
ounterstain. Negative controls were treated with identical
rocedures without primary antibody. The results of posi-
ive staining were verified by two blinded investigators
ndependently.
Bone marrow transplantation. After bone marrow
ingle-cell suspensions were prepared in Hank’s salt solu-
ion under aseptic conditions, male mice that received
ethal irradiation (10 Gy in one dose at a rate of 2 Gy/min,
BR-1520r Hitachi irradiator; Hitachi, Tokyo, Japan)
ere injected with 5  106 bone marrow cells via tail vein
n the second day following irradiation. Reconstitution of
he mice with donor bone marrow was confirmed by detec-
ion of CD44 expression by flow cytometry in splenocytes
solated from recipient mice.
Flow cytometry detection of CD44 expression on
ultured VSMCs. Briefly, cells suspended in 100 L of
BS solution were incubated with FITC-conjugated CD44
Ab (FITC rat anti-mouse; BD Pharmingen, San Diego,
alif) for 15 minutes at room temperature. Cells were then
ashed with PBS and analyzed with a FACScan (Becton
ickinson and Co, Mountain View, Calif). Rat FITC-
onjugated IgG2a (BD Pharmingen) was used as a negative
ontrol. The experiment was repeated three times.
RT-PCR. Total RNA was extracted from femoral ar-
eries (five mice per group) or cultured mouse VSMCs: 1.5
g total RNAwas used to perform RT-PCR tomeasure the
D44mRNA level with one-step RT-PCR kit (SuperScript
ne-step RT-PCR Platinum Tag HiFi Kit; Invitrogen,
arlsbad, Calif). The primer pairs for CD44 were (5=GGC-
ACTAGATCCCTCCGTT3=; 5=ACCCAGAGGCAT-
CCAGCTG3=) and the housekeeping gene GAPDH
as (5=AAGGTCGGAGTCAACGGATT3=; 5=CTGG-
AGATGGTGATGGGAT3=) and were purchased from
igma Genosys (St. Louis, Mo).
n  5.
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Volume 53, Number 5 Zhao et al 1367.e2upplementary Fig 3, online only. Time course study on CD44
RNA expression on the cultured mouse VSMCs incubated with
ow molecular weight (LMW) heparin. Time course study on the
ffects of LMW heparin at a concentration of 100 g/mL on the
xpression of CD44 mRNA revealed that LMW heparin increased
D44 expression in a time-dependent manner. mRNA expression
eached the highest level on the fourth incubating day (RT-PCR
etection of CD44 mRNA expression). GADPH, Glyceraldehyde-
-phosphate dehydrogenase.Supplementary Fig 1, online only. Low molecular weight
(LMW) heparin decreased proliferating cell nuclear antigen
(PCNA) expression in the injured femoral arteries in CD44 /
mice. LMW heparin reduced proliferating cell nuclear antigen
(PCNA) expression in injured femoral arteries, whereas warfarin-
or saline-treated femoral arteries did not show any changes in
PCNA expression, indicating an antiproliferative role of LMW
heparin in the process of vascular remodeling, and this property of
heparin was not due to its anticoagulant activity (Western blot
detection of CD44 expression). Each group, n  5. GADPH, Glyc-
eraldehyde-3-phosphate dehydrogenase.
Supplementary Fig 2, online only. Low molecular weight
(LMW) heparin upregulated CD44 mRNA expression in the in-
jured CD44/ femoral arteries. The injured CD44/ femoral
arteries did not show a significant change of CD44 mRNA expres-
sion compared with that of the uninjured CD44/ artery. When
treated with LMW heparin, the injured femoral arteries expressed
much higher CD44 mRNA (RT-PCR detection of CD44 mRNA
expression) in the fourth week after the injury, whereas warfarin or
saline did not affect the expression of CD44 mRNA. Each group,
1 2
femoral artery, Elastin van Gieson staining, arrows indicate in
rin, respectively).
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May 20111367.e3 Zhao et alulate the wall thickness percentage (WT%). Based on the
f Health, Bethesda, Md), we measured the OD1, OD2,
calculated the WT% (injury-induced remodeled mouse
ternal elastic lamina).Supplementary Fig 4, online only. How tomeasure and calc
image analysis software ImageJ v. 1.33u (National Institutes o
ID , and ID , and then calculated mOD, mWT. Finally, weSupplementary Fig 5, online only. Low molecular weight
(LMW) heparin upregulated CD44 protein expression in the in-
jured CD44/ femoral arteries. In CD44/mice, the injured
arteries did not show a significant change of CD44 expression
compared with the uninjured CD44/ mice. When treated with
LMW heparin, the injured femoral arteries expressed much higher
CD44 protein (IHC detection of CD44 protein, a, b, and c represent
sham, injured, and injured femoral artery treated with LMW hepa-
